Alan Franklin, MD, PhD, Chief Medical Officer, RFE Pharma, provides an update on lead compound RFE-007-CAI (carboxyamidotriazole), which the company has reformulated as an anti-angiogenic intravitreal injectable formulation.
2 / 11 Series: OIS RETINA 2018
post as anonymous